Hypoglycemia

In diabetes care, blood glucose below 70 mg/dL should prompt treatment action. CDC identifies glucose below 54 mg/dL as severe low blood sugar, a level at which syncope and need for assistance may occur. CDCCDCLow Blood Sugar (Hypoglycemia) | Diabetes

For clinical documentation and risk stratification, severe hypoglycemia is best defined by an episode of severe cognitive impairment requiring external assistance to administer carbohydrate, glucagon, or another corrective action. This definition does not require a measured glucose value and includes coma or convulsions. PubMedPubMedDefinitions of Severe Hypoglycemia - Clinical Review Report: Glucagon Nasal Powder (Baqsimi) - NCBI Bookshelf

If a point-of-care glucose result conflicts with the clinical presentation, interpret it in the context of the device indication and its limitations; point-of-care and laboratory results should be correlated with clinical findings. fdafda1 Free State Reporting, Inc. 1378 Cape St. Claire Road ...

For a conscious patient who can take oral treatment safely, use a readily absorbable carbohydrate source. A review of insulin-associated hypoglycemia reports that approximately 15 to 20 g of dextrose typically restores euglycemia in adults, while pediatric dosing should be weight-based. Foods high in fat may delay carbohydrate absorption and recovery. PubMedPubMedInsulin Therapy and Hypoglycemia

For severe hypoglycemia, IV dextrose followed by glucose infusion is an accepted approach. If oral treatment cannot be given, glucagon may be administered; current formulations include intramuscular and intranasal options. PubMedPubMedHypoglycemia - StatPearls - NCBI Bookshelf

Do not assume glucagon will provide durable correction. Its duration may be shorter than the causal process, so serial glucose assessment and definitive management of the cause are required. PubMedPubMedGlucagon - StatPearls - NCBI Bookshelf

In patients receiving glucose-lowering therapy, review the temporal relation to insulin, sulfonylureas, or meglitinides, food intake, alcohol exposure, activity, and acute illness. Advanced CKD heightens risk, especially with insulin and insulin-secretagogue therapies, and daily glucose monitoring may be insufficiently feasible for some patients. Kidney International+1Kidney InternationalKDIGO 2022 Clinical Practice Guideline for Diabetes ...PubMedTreatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach

Recurrent hypoglycemia without an apparent cause warrants endocrinology evaluation. In patients without diabetes or without a clear iatrogenic driver, document Whipple triad before extensive evaluation: compatible symptoms, low measured glucose, and symptom resolution after glucose administration. NEJM+2NEJMNEJMcpc1802828_discussion_1cdn clinicaltrials919.659.5677919.659.5677PubMedHypoglycemia - StatPearls - NCBI Bookshelf

When endogenous hyperinsulinemia is suspected, obtain critical biochemical samples during spontaneous hypoglycemia or a supervised provocative evaluation directed by endocrinology. Whipple triad with hyperinsulinemia and elevated C-peptide is strongly associated with insulinoma, although rare causes such as adult-onset nesidioblastosis exist. JAMAJAMAAdult-Onset Nesidioblastosis Causing Hypoglycemia

Hypoglycemia avoidance is a central quality and safety objective in diabetes care, but historical performance measures have emphasized surrogate glycemic metrics more often than hypoglycemia prevention. JAMAJAMAInclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients After an event, prioritize reduction of recurrent hypoglycemia rather than pursuing glycemic targets without regard to treatment burden and safety.

For individuals at high risk, the Endocrine Society guideline update highlights wider use of continuous glucose monitors, insulin pumps, and newer glucagon formulations as contemporary components of hypoglycemia management. support endocrinesupport endocrineNew Endocrine Society Clinical Practice Guideline examines better ways to manage hypoglycemia in people with diabetes | Endocrine Society Technology selection should be individualized to recurrent events, impaired awareness, treatment complexity, and the patient’s capacity to use alerts and rescue therapies.

Hypoglycemia unawareness deserves active identification. Recurrent hypoglycemia contributes to hypoglycemia-associated autonomic failure, creating a cycle of impaired warning symptoms and additional severe events. PubMedPubMedManaging Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies - PMC A review reports that avoidance of hypoglycemia for weeks may improve awareness or counterregulation in some patients, although this is not a substitute for individualized regimen modification. PubMedPubMedInsulin Therapy and Hypoglycemia